UBS upgrades Charles River Laboratories stock to Strong Buy

Published on 10/07/2026 at 01:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CRL targets 5.00 percent to 7.00 percent organic growth through 2030. Charles River Laboratories stock had EUR 273.20 prior close on October 5, 2026.

CRL, US1598641074, Illustration mit AI erstellt.

Charles River Laboratories stock is tied to a Strong Buy upgrade by UBS Group, while the company is pursuing 5.00 percent to 7.00 percent organic revenue growth through 2030. MarketBeat reported the UBS upgrade on October 1, 2026.

UBS upgrade meets long-term targets

UBS Group upgraded Charles River Laboratories International to Strong Buy, according to MarketBeat's October 1 report. The article also cited an average analyst price target of USD 300.11 and a consensus rating of Moderate Buy.

The upgrade follows the company's September 24 Investor Day. In its release, Charles River Laboratories reaffirmed 2026 organic revenue growth at the upper end of a 0.00 percent to 1.00 percent range and said non-GAAP earnings per share should reach the upper end of USD 11.15 to USD 11.45.

Growth target raises the bar

The 2030 target of 5.00 percent to 7.00 percent annual organic revenue growth is materially above the upper end of the 2026 range. The company also expects its Create the Future program to generate more than USD 300.00 million in cumulative savings from 2027 through 2030, with automation and digital tools at the center of the plan.

For investors, the key test is execution rather than the target alone. The same release sets a 2030 non-GAAP operating margin target of 24.00 percent, compared with a 2026 guidance range of 21.00 percent to 21.30 percent, while the long-term targets exclude future acquisitions and divestitures.

NYSE quote stays below yearly high

The prior close at Lang & Schwarz was EUR 273.20 on October 5, 2026. On the NYSE, Charles River Laboratories closed at USD 304.96 on October 6, 2026 at 4:00 p.m. EDT, against a 52-week range of USD 146.20 to USD 333.30 and a market capitalization of USD 14.7 billion.

The further course of trading is shown by the continuously updated real-time quote of Charles River Laboratories stock.